PMID: 22582541May 16, 2012Paper

Beta-blockers for heart failure: an evidence based review answering practical therapeutic questions

The Medical Journal of Malaysia
H T OngF P Kow

Abstract

Beta-blockers are underutilised in heart failure because clinicians may be unsure whether all beta-blockers are useful, how therapy should be initiated and whether beta-blockers are contraindicated in some patients. Bisoprolol, carvedilol and metoprolol succinate have been clearly proven to reduce mortality and hospitalisation in patients with Class II to IV heart failure; limited evidence also support short-acting metoprolol tartrate and nebivolol. Initiating dose should be very low (1.25 mg bisoprolol, 3.125 mg carvedilol, 12.5 mg metoprolol succinate) and increased gradually over weeks. Treatment benefit appears proportional to magnitude of heart rate reduction and thus target dose should be the maximum tolerated for adequate bradycardia. Even in decompensated heart failure or those with coexisting bronchospasm, beta-blockers are not contraindicated although the dose may have to be reduced or withheld temporarily. The consistent trial data should reassure clinicians and encourage them to confidently initiate beta blockers in patients with systolic heart failure.

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Related Papers

Cleveland Clinic Journal of Medicine
W H Wilson TangGary S Francis
Tijdschrift voor gerontologie en geriatrie
C W Middeljans-Tijssen, R W M M Jansen
Arquivos brasileiros de cardiologia
Fabiana MarquesMarcus Vinícius Simões
Arquivos brasileiros de cardiologia
José Albuquerque de Figueiredo NetoCésar Grupi
© 2021 Meta ULC. All rights reserved